Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

Affiliation auteurs!!!! Error affiliation !!!!
TitreUnicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
Type de publicationJournal Article
Year of Publication2021
AuteursConroy T., Hammel P., Turpin A., Belletier C., Wei A., Mitry E., Lopez A., Francois E., Artru P., Biagi J., Lecomte T., Assenat E., Faroux R., Ychou M., Bouche O., Lambert A., Monard L., Rat P., Castan F., Bachet J.B
JournalANNALS OF ONCOLOGY
Volume32
PaginationS1334
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2021.08.2137